

Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

SECTION 1. IDENTIFICATION

Product identifier : Cyclosporine Formulation

Other means of identification : Optimmune (A007869)

OPTIMMUNE OPHTHALMIC OINTMENT (51551)

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530

Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard

Carcinogenicity : Category 1B

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :

. Dansar

Signal Word : Danger

Hazard Statements : H350 May cause cancer.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:



Cyclosporine Formulation

Version **Revision Date:** SDS Number: Date of last issue: 06.07.2024 28.09.2024 608873-00022 Date of first issue: 08.04.2016 4.1

P405 Store locked up.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

| Chemical name | CAS-No. | Classification | Concentration (% w/w) |
|---------------|------------|--|-----------------------|
| Petrolatum | 8009-03-8 | | >= 50 -< 70 |
| Cyclosporine | 59865-13-3 | Acute Tox. (Oral), 4 Carc., 1B Repr., 1B STOT RE, (Kidney, Liver, Immune sys- tem), 1 | >= 0,1 -< 0,3 |

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention.

Wash clothing before reuse. Thoroughly clean shoes before reuse.

Flush eyes with water as a precaution. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

May cause cancer.

delaved

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical



Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe vapors or spray mist.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--------------|------------|---|--|----------|
| Petrolatum | 8009-03-8 | TWA (Inhalable particulate matter) | 5 mg/m³ | ACGIH |
| Cyclosporine | 59865-13-3 | TWA | 10 μg/m3 (OEB 3) | Internal |
| | | Wipe limit | 100 μg/100 cm ² | Internal |

Engineering measures: Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection

Combined particulates and organic vapor type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : ointment

Color : colorless, to, light yellow

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available



Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition

products

: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation exposure Skin contact

Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Petrolatum:



Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Method: OECD Test Guideline 401

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Cyclosporine:

Acute oral toxicity : LD50 (Rat): 1.480 mg/kg

LD50 (Mouse): 2.329 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Mouse): 107 mg/kg Application Route: Intravenous

LD50 (Rat): 25,8 mg/kg

Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:

Petrolatum:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Cyclosporine:

Remarks : No data available

May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Petrolatum:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Remarks : Based on data from similar materials



Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

Cyclosporine:

Remarks : No data available

May irritate eyes.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Petrolatum:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Cyclosporine:

Remarks : May cause sensitization of susceptible persons.

Germ cell mutagenicity

Not classified based on available information.

Components:

Petrolatum:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Cyclosporine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster cells

Result: negative

Test Type: sister chromatid exchange assay

Result: positive



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Chinese hamster Cell type: Bone marrow

Result: negative

Test Type: Chromosomal aberration

Species: Mouse Result: negative

Carcinogenicity

May cause cancer.

Components:

Petrolatum:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Cyclosporine:

Species : Mouse
Application Route : Oral
Exposure time : 78 weeks

LOAEL : 4 mg/kg body weight

Result : positive

Target Organs : Liver, lymphatic system

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 0,5 mg/kg body weight

Result : positive Target Organs : Pancreas

Species : Humans

Result : May cause cancer.

Target Organs : Immune system, Skin

Remarks : Information taken from reference works and the literature.

Carcinogenicity - Assess-

ment

May cause cancer.

Reproductive toxicity

Not classified based on available information.

Components:

Petrolatum:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

test

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Skin contact

Result: negative

Remarks: Based on data from similar materials

Cyclosporine:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity F1: LOAEL: 15 mg/kg body weight

Result: No effects on fertility., Effect on reproduction capacity.

Test Type: Fertility Species: Rat, males

Application Route: Subcutaneous Fertility: LOAEL: 10 mg/kg body weight

Result: Reduced fertility

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 30 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced fetal weight., Fetal mortality., Retardations., Teratogen-

ic effects.

Test Type: Embryo-fetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced fetal weight., Fetal mortality., Retardations., Teratogen-

ic effects.

Test Type: Development

Species: Rabbit

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Target Organs: Kidney

Result: Visceral malformations.

Test Type: Development

Species: Rat

Application Route: Intravenous

Developmental Toxicity: LOAEL: 12 mg/kg body weight

Target Organs: Heart



Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

Result: Visceral malformations.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Components:

Cyclosporine:

Target Organs : Kidney, Liver, Immune system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Petrolatum:

Species : Rat

NOAEL : 5.000 mg/kg
Application Route : Ingestion
Exposure time : 2 y

Cyclosporine:

Species : Rat

NOAEL : 14 mg/kg

LOAEL : 45 mg/kg

Application Route : Oral

Exposure time : 90 Days

Target Organs : Kidney, Liver, Immune system

Symptoms : hair loss

Species: MonkeyNOAEL: 20 mg/kgLOAEL: 60 mg/kgApplication Route: OralExposure time: 90 Days

Target Organs : Immune system

Symptoms : Gastrointestinal disturbance, Liver disorders, Kidney disorders

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 12 Months
Target Organs : Immune system

Symptoms : Changes in the blood count, Kidney disorders, Skin disorders,

hair loss

Aspiration toxicity

Not classified based on available information.



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

Experience with human exposure

Components:

Cyclosporine:

Inhalation : Remarks: May cause irritation of respiratory tract.

Skin contact : Remarks: May irritate skin.

Eye contact : Symptoms: Eye irritation, eye pain

Ingestion : Symptoms: Kidney disorders, Tremors, hypertension, blood

effects, Gastrointestinal disturbance

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Petrolatum:

Toxicity to fish : LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10.000 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

NOEL (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 10 mg/l

Exposure time: 21 d

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Persistence and degradability

Components:

Petrolatum:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 31 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Remarks: Based on data from similar materials

Bioaccumulative potential

No data available



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

ANTT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH)

Group 1: Carcinogenic to humans

Cyclosporine 59865-13-3

Brazil. List of chemicals controlled by the Federal : Not applicable

Police

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined



Cyclosporine Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 4.1 28.09.2024 608873-00022 Date of first issue: 08.04.2016

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 28.09.2024 Date format : dd.mm.yyyy

Further information

Data Sheet

Sources of key data used to compile the Material Safety

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided



Cyclosporine Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 4.1
 28.09.2024
 608873-00022
 Date of first issue: 08.04.2016

relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8